Maximum weight loss (20%+ body weight) Achieving 20 percent or greater weight loss consistently requires the higher dose levels of 10mg to 15mg weekly, maintained over nine months to a year or longer
Mounjaro (tirzpatide) : double agoniste GLP-1/GIP, -20,9 % de poids (SURMOUNT-1) mdicament autoris, rembours sous conditions ds le 15 juin 2026 Retatrutide : triple agoniste GLP-1/GIP/glucagon, -28,3 % 80 semaines (TRIUMPH-1, phase 3) molcule de recherche, non commercialise avant ~2028 cart d'environ +7 +8 points en faveur du retatrutide, en comparaison indirecte (aucun essai tte--tte) Retatrutide vs Mounjaro : la rponse directe En comparaison indirecte des essais pivots, le retatrutide dpasse le Mounjaro sur la perte de poids : -28,3 % (TRIUMPH-1, 12 mg, 80 semaines) contre -20,9 % pour le tirzpatide (SURMOUNT-1, 15 mg, 72 semaines), soit environ +7 +8 points
These include your current glycaemic control (HbA1c levels), body weight trajectory, other diabetes medications you are taking, and your overall cardiovascular risk profile
Walking around the city not only increased her level of physical activity but also contributed to her overall health and well-being
